Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPECIA vs ATMEKSI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Finasteride is a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme that converts testosterone to dihydrotestosterone (DHT). By inhibiting 5α-reductase, finasteride reduces serum and intraprostatic DHT levels, decreasing androgenic stimulation of the prostate. In hair follicles, reduction of DHT levels slows hair loss and promotes hair regrowth.
ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.
Treatment of male pattern hair loss (androgenetic alopecia) in men only,Treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate
Treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg,Off-label use as part of antiretroviral therapy in treatment-experienced patients with viral suppression
1 mg orally once daily
1.5 mg/kg IV every 4 weeks
Terminal elimination half-life is approximately 6-8 hours in young adults (range 4-12 hours), with clinical relevance for once-daily dosing; slightly prolonged in elderly (8-11 hours).
Terminal elimination half-life is 12 hours; renally impaired patients have prolonged half-life up to 24 hours.
Finasteride is extensively metabolized in the liver, primarily via the cytochrome P450 3A4 enzyme system. Two major metabolites, t-butyl side chain hydroxylation and ω-hydroxylation, have been identified; these metabolites possess less than 20% of the 5α-reductase inhibitory activity of finasteride.
Atazanavir is metabolized by CYP3A4; cobicistat is metabolized by CYP3A and to a minor extent by CYP2D6.
Primarily hepatic metabolism; 57% excreted in feces (as metabolites), 39% in urine (as metabolites, <0.1% as unchanged finasteride).
Primarily renal (80% unchanged) and biliary/fecal (15% as metabolites).
Approximately 93% bound to plasma proteins (mainly albumin).
95% bound to albumin and alpha-1-acid glycoprotein.
Approximately 1.1 L/kg (range 0.9-1.3 L/kg), indicating extensive tissue distribution with penetration into seminal fluid and scalp tissue.
2.0 L/kg, indicating extensive tissue distribution.
Oral bioavailability is approximately 65% (range 60-70%); not affected by food.
Oral: 60-70% due to first-pass metabolism.
No dose adjustment required for any degree of renal impairment
GFR 15-29 m L/min: 1.0 mg/kg IV every 4 weeks; GFR <15 m L/min: not recommended
No dose adjustment recommended; no studies in hepatic impairment
Child-Pugh A: no adjustment; Child-Pugh B: 1.0 mg/kg IV every 4 weeks; Child-Pugh C: not recommended
Not indicated in pediatric patients; safety and efficacy not established
Age 2-17 years: 1.5 mg/kg IV every 4 weeks; maximum 120 mg per dose
No specific dose adjustment; limited data in elderly men with benign prostatic hyperplasia
No specific adjustment; monitor renal function and reduce dose if GFR <30 m L/min
PROPECIA is not approved for use in women or children. Finasteride is contraindicated in women who are or may become pregnant due to risk of abnormalities of the external genitalia of a male fetus. Women should not handle crushed or broken tablets when pregnant or may be pregnant.
None
Risk of prostate cancer: Finasteride may increase the risk of high-grade prostate cancer; digital rectal exam and PSA screening recommended before and during therapy.,Sexual dysfunction: Decreased libido, erectile dysfunction, ejaculation disorders, and decreased ejaculate volume have been reported; may persist after discontinuation.,Depression and suicidal ideation: Monitor for mood changes.,Breast cancer: Reported in men; evaluate any breast changes promptly.,Elevated PSA levels: Use caution interpreting PSA values in men on finasteride; adjust PSA levels by approximately 50% for clinical interpretation.,Hepatic impairment: Use with caution in patients with liver function abnormalities.,Pediatric use: Not indicated for use in children.
Hepatotoxicity, especially in patients with pre-existing liver disease or elevated transaminases,Nephrolithiasis and cholelithiasis,Cardiac conduction abnormalities (PR interval prolongation),Risk of developing resistance if not used with other antiretrovirals,Renal impairment (cobicistat decreases estimated creatinine clearance)
Hypersensitivity to finasteride or any component of the formulation,Women who are or may become pregnant (due to risk of hypospadias in male fetuses),Children (not indicated for use in pediatric patients)
Concomitant use with drugs highly dependent on CYP3A for clearance (e.g., alfuzosin, rifampin, ergot derivatives, St. John's wort, lovastatin, simvastatin, sildenafil for pulmonary arterial hypertension),Severe hepatic impairment (Child-Pugh Class B or C)
No clinically significant food interactions. May be taken with or without food. However, avoid excessive alcohol intake as it may exacerbate certain side effects (e.g., dizziness).
Avoid alcohol (may exacerbate CNS effects). Grapefruit juice may increase atomoxetine exposure; limit consumption. High-fat meals do not significantly affect absorption.
Contraindicated in females of childbearing potential. Finasteride inhibits conversion of testosterone to DHT, and risk of hypospadias in male fetuses if exposure occurs during gestation. No adequate studies in pregnant women; animal studies show abnormal external genitalia in male offspring at doses 1-100 times human exposure.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: No known fetal risks. Avoid use during organogenesis unless benefit outweighs risk.
Not recommended. M/P ratio unknown. Finasteride is excreted in rat milk; no human data.
Not recommended during breastfeeding. M/P ratio unknown. Excreted in animal milk; potential for serious adverse reactions in nursing infants.
No dose adjustments applicable as drug is contraindicated in pregnancy.
No dose adjustment required in pregnancy. Pharmacokinetic profile unchanged.
Monitor patients for sexual dysfunction (e.g., decreased libido, erectile dysfunction) which may persist after discontinuation. Finasteride lowers serum PSA by approximately 50%; when interpreting PSA values in men taking Propecia, double the measured value for prostate cancer screening. Use with caution in patients with liver impairment; hepatic metabolism is primary clearance route. Avoid handling crushed or broken tablets in women who are or may become pregnant due to risk of teratogenicity (fetal genital abnormalities). Onset of hair regrowth typically takes 3-6 months; continue use for at least 12 months before assessing efficacy.
ATMEKSI (atomoxetine) is a selective norepinephrine reuptake inhibitor (NRI) indicated for ADHD. It has a slower onset of action (2-4 weeks) compared to stimulants. Monitor for hepatotoxicity and suicidal ideation, especially in children and adolescents. Use cautiously with hepatic impairment (reduce dose) and CYP2D6 poor metabolizers (need lower dose). Avoid concurrent MAOIs. May cause orthostatic hypotension and urinary retention.
Take exactly as prescribed, usually one tablet (1 mg) daily with or without food.,Do not stop or skip doses without consulting your doctor; continuous use is needed to maintain benefit.,It may take 3-6 months to see hair regrowth and up to 12 months for full effect.,Report any new or worsening sexual side effects (e.g., decreased libido, erectile dysfunction, ejaculation disorders) promptly.,Finasteride may increase the risk of high-grade prostate cancer; discuss screening risks with your doctor.,Do not donate blood while taking Propecia and for at least 1 month after stopping to prevent exposure to pregnant women.,Women who are pregnant or may become pregnant should not handle crushed or broken tablets due to risk of birth defects.,If a dose is missed, skip it and take the next dose at the usual time; do not double up.
Take ATMEKSI exactly as prescribed; do not change dose without consulting your doctor.,It may take 2-4 weeks to notice improvement in symptoms.,Avoid alcohol and grapefruit juice as they may affect drug levels.,Report any signs of liver problems (yellowing of skin/eyes, dark urine, abdominal pain) or suicidal thoughts immediately.,May cause dizziness or fainting, especially when standing up; rise slowly.,Do not stop abruptly without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROPECIA vs ATMEKSI, answered by our medical review team.
PROPECIA is a 5-alpha reductase inhibitor that works by Finasteride is a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme that converts testosterone to dihydrotestosterone (DHT). By inhibiting 5α-reductase, finasteride reduces serum and intraprostatic DHT levels, decreasing androgenic stimulation of the prostate. In hair follicles, reduction of DHT levels slows hair loss and promotes hair regrowth.. ATMEKSI is a PDE5 Inhibitor that works by ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROPECIA and ATMEKSI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROPECIA is: 1 mg orally once daily. The standard adult dose of ATMEKSI is: 1.5 mg/kg IV every 4 weeks. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROPECIA and ATMEKSI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROPECIA is classified as Category C. Contraindicated in females of childbearing potential. Finasteride inhibits conversion of testosterone to DHT, and risk of hypospadias in male fetuses if exposure occurs during gest. ATMEKSI is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: No known fetal risks. Avoid use during organogenesis u. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.